FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001378972> ?p ?o ?g. }

• W2001378972 endingPage "e94471" @default.
• W2001378972 startingPage "e94471" @default.
• W2001378972 abstract "Clinical guidelines suggest neoadjuvant cisplatin-based chemotherapy prior to cystectomy in the setting of muscle-invasive bladder cancer (MIBC). A creatinine clearance (CrCl) >60 mL/min is frequently used to characterize cisplatin-eligible patients, and use of the CKD-EPI equation to estimate CrCl has been advocated. From a prospectively maintained institutional database, patients with MIBC who received cystectomy were identified and clinicopathologic information was ascertained. CrCl prior to surgery was computed using three equations: (1) Cockcroft-Gault (CG), (2) CKD-EPI, and (3) MDRD. The primary objective was to determine if the CG and CKD-EPI equations identified a different proportion of patients who were cisplatin-eligible, based on an estimated CrCl of >60 mL/min. Cisplatin-eligibility was also assessed in subsets based on age, CCI score and race. Actuarial rates of neoadjuvant cisplatin-based chemotherapy use were also reported. Of 126 patients, 70% and 71% of patients were found to be cisplatin-eligible by the CKD-EPI and CG equations, respectively (P = 0.9). The MDRD did not result in significantly different characterization of cisplatin-eligibility as compared to the CKD-EPI and CG equations. In the subset of patients age >80, the CKD-EPI equation identified a much smaller proportion of cisplatin-eligible patients (25%) as compared to the CG equation (50%) or the MDRD equation (63%). Only 34 patients (27%) received neoadjuvant cisplatin-based chemotherapy. Of the 92 patients who did not receive neoadjuvant chemotherapy, 64% had a CrCl >60 mL/min by CG. In contrast to previous reports, the CKD-EPI equation does not appear to characterize a broader span of patients as cisplatin-eligible. Older patients (age >80) may less frequently be characterized as cisplatin-eligible by CKD-EPI. The discordance between actual rates of neoadjuvant chemotherapy use and rates of cisplatin eligibility suggest that other factors (e.g., patient and physician preference) may guide clinical decision-making." @default.
• W2001378972 created "2016-06-24" @default.
• W2001378972 creator A5021442340 @default.
• W2001378972 creator A5039978200 @default.
• W2001378972 creator A5041033274 @default.
• W2001378972 creator A5048898780 @default.
• W2001378972 creator A5055433398 @default.
• W2001378972 creator A5059219836 @default.
• W2001378972 creator A5067290064 @default.
• W2001378972 creator A5068397348 @default.
• W2001378972 date "2014-04-10" @default.
• W2001378972 modified "2023-09-25" @default.
• W2001378972 title "CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer" @default.
• W2001378972 cites W1757342161 @default.
• W2001378972 cites W1974722941 @default.
• W2001378972 cites W1975918912 @default.
• W2001378972 cites W2026826756 @default.
• W2001378972 cites W2036433572 @default.
• W2001378972 cites W2055864845 @default.
• W2001378972 cites W2068100145 @default.
• W2001378972 cites W2072808406 @default.
• W2001378972 cites W2083397917 @default.
• W2001378972 cites W2100115521 @default.
• W2001378972 cites W2103561213 @default.
• W2001378972 cites W2110921920 @default.
• W2001378972 cites W2122063636 @default.
• W2001378972 cites W2152762320 @default.
• W2001378972 cites W2155839160 @default.
• W2001378972 cites W2155965977 @default.
• W2001378972 cites W2166453367 @default.
• W2001378972 cites W2240844634 @default.
• W2001378972 doi "https://doi.org/10.1371/journal.pone.0094471" @default.
• W2001378972 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3983198" @default.
• W2001378972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24722472" @default.
• W2001378972 hasPublicationYear "2014" @default.
• W2001378972 type Work @default.
• W2001378972 sameAs 2001378972 @default.
• W2001378972 citedByCount "8" @default.
• W2001378972 countsByYear W20013789722016 @default.
• W2001378972 countsByYear W20013789722018 @default.
• W2001378972 countsByYear W20013789722021 @default.
• W2001378972 crossrefType "journal-article" @default.
• W2001378972 hasAuthorship W2001378972A5021442340 @default.
• W2001378972 hasAuthorship W2001378972A5039978200 @default.
• W2001378972 hasAuthorship W2001378972A5041033274 @default.
• W2001378972 hasAuthorship W2001378972A5048898780 @default.
• W2001378972 hasAuthorship W2001378972A5055433398 @default.
• W2001378972 hasAuthorship W2001378972A5059219836 @default.
• W2001378972 hasAuthorship W2001378972A5067290064 @default.
• W2001378972 hasAuthorship W2001378972A5068397348 @default.
• W2001378972 hasBestOaLocation W20013789721 @default.
• W2001378972 hasConcept C105795698 @default.
• W2001378972 hasConcept C121608353 @default.
• W2001378972 hasConcept C126322002 @default.
• W2001378972 hasConcept C126894567 @default.
• W2001378972 hasConcept C143998085 @default.
• W2001378972 hasConcept C159641895 @default.
• W2001378972 hasConcept C27403532 @default.
• W2001378972 hasConcept C2775910329 @default.
• W2001378972 hasConcept C2776694085 @default.
• W2001378972 hasConcept C2778239845 @default.
• W2001378972 hasConcept C2778292576 @default.
• W2001378972 hasConcept C2780352672 @default.
• W2001378972 hasConcept C33923547 @default.
• W2001378972 hasConcept C530470458 @default.
• W2001378972 hasConcept C71924100 @default.
• W2001378972 hasConceptScore W2001378972C105795698 @default.
• W2001378972 hasConceptScore W2001378972C121608353 @default.
• W2001378972 hasConceptScore W2001378972C126322002 @default.
• W2001378972 hasConceptScore W2001378972C126894567 @default.
• W2001378972 hasConceptScore W2001378972C143998085 @default.
• W2001378972 hasConceptScore W2001378972C159641895 @default.
• W2001378972 hasConceptScore W2001378972C27403532 @default.
• W2001378972 hasConceptScore W2001378972C2775910329 @default.
• W2001378972 hasConceptScore W2001378972C2776694085 @default.
• W2001378972 hasConceptScore W2001378972C2778239845 @default.
• W2001378972 hasConceptScore W2001378972C2778292576 @default.
• W2001378972 hasConceptScore W2001378972C2780352672 @default.
• W2001378972 hasConceptScore W2001378972C33923547 @default.
• W2001378972 hasConceptScore W2001378972C530470458 @default.
• W2001378972 hasConceptScore W2001378972C71924100 @default.
• W2001378972 hasIssue "4" @default.
• W2001378972 hasLocation W20013789721 @default.
• W2001378972 hasLocation W20013789722 @default.
• W2001378972 hasLocation W20013789723 @default.
• W2001378972 hasLocation W20013789724 @default.
• W2001378972 hasLocation W20013789725 @default.
• W2001378972 hasOpenAccess W2001378972 @default.
• W2001378972 hasPrimaryLocation W20013789721 @default.
• W2001378972 hasRelatedWork W1987461627 @default.
• W2001378972 hasRelatedWork W2001378972 @default.
• W2001378972 hasRelatedWork W2012557700 @default.
• W2001378972 hasRelatedWork W2122063636 @default.
• W2001378972 hasRelatedWork W2598074874 @default.
• W2001378972 hasRelatedWork W2603025253 @default.
• W2001378972 hasRelatedWork W2907753846 @default.
• W2001378972 hasRelatedWork W2980761415 @default.
• W2001378972 hasRelatedWork W4229366546 @default.

• next